The IMMY sõna Aspergillus GM lateral flow assay (LFA) can facilitate the introduction of local site testing to support clinical decision making when managing high-risk patients such as haemato-oncology and solid organ transplant recipients, as well as critical care patients who may be at risk of invasive aspergillosis.  

Early diagnosis of invasive fungal disease (IFD) is challenging, leading to the development of increasingly detailed diagnostic strategies, and testing regimens for different patient demographics.  The importance of timely diagnosis for patients can be pivotal but testing turnaround times may be influenced both by technique and off-site referral.  The development of rapid tests for biomarkers, such as Aspergillus Galactomannan (GM), can enable adoption of in-house testing bringing the process closer to both clinicians and patients.

Suitable for use with both BAL (Broncheal Alveolar Lavage) and serum samples, the sõna Aspergillus GM LFA and dedicated Cube Reader provide both a qualitative result and a GM index value in under an hour.  Tests can be performed individually so there is no requirement for batching which can also help improve service turnaround times.

The IMMY range of lateral flow assays, available from Alpha Laboratories, provide simple-to-use, rapid diagnostic assays to aid fungal disease detection and support early diagnosis and patient management.

Please visit www.alphalabs.co.uk for further information or click on the Request Information button below.